Christian Gratzke

1 week ago | urologytimes.com | Christian Gratzke |Benjamin P. Saylor

A recent study published in NEJM Evidence investigated the impact of conservative management, specifically an app-based therapeutic, on lower urinary tract symptoms (LUTS) in men.1 The 12-week randomized controlled trial involved over 200 men with LUTS, who were randomly assigned to an intervention group using the app in addition to their usual medication, or control group maintaining their regular medication.

Jan 9, 2025 | mdpi.com | Isis Wolf |Susanne Schultze-Seemann |Christian Gratzke |Philipp Wolf

Altmetric announcement Help format_quote Cite thumb_up ... Endorse Need Help? Find support for a specific problem in the support section of our website. Please let us know what you think of our products and services. Visit our dedicated information section to learn more about MDPI.

Oct 3, 2024 | preprints.org | Christian Gratzke |Philipp Wolf |Isis Wolf |Susanne Schultze-Seemann

Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 2 October 2024 / Approved: 3 October 2024 / Online: 3 October 2024 (12:07:53 CEST) Wolf, I.; Schultze-Seemann, S.; Gratzke, C.; Wolf, P. Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer. Preprints 2024, 2024100247. https://doi.org/10.20944/preprints202410.0247.v1 Wolf, I.; Schultze-Seemann, S.; Gratzke, C.; Wolf, P.

May 14, 2024 | europeanurology.com | Marcus J. Drake |Christian Gratzke |Kari A.O. Tikkinen |Rouen Cedex

Abstract Symptomatic benefit and urodynamic obstruction relief represent relevant outcomes of therapies for lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). We summarized evidence from studies concurrently assessing variations in terms of symptoms severity and invasive urodynamic measures of obstruction following medical and surgical therapies for LUTS/BPH. We performed a systematic review of PubMed, Scopus, and Web of Science in June 2023.

Apr 11, 2024 | europeanurology.com | Markus Grabbert |Christian Gratzke

Fizazi K, Bernard-Tessier A, Roubaud G, et alNEJM Evid 2024;3:EVIDoa2300171[1]Fizazi K. Bernard-Tessier A. Roubaud G. et al. Targeted inhibition of CYP11A1 in castration-resistant prostate cancer. NEJM Evid.